In fact, we just passed a major milestone by completing the hiring of our U.S. sales force, and we could not be more pleased by the quality of these sales professionals. They averaged 20 years' experience in the industry, including eight years of recent work in rare disease, and all of them have been consistent top-tier performers. What we hear over and over is they join BioCryst because they really want to sell the first targeted oral drug for HAE, and they can't wait to bring Orladeyo to patients.